NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials
Zainul Abedin Kapacee(The Christie NHS Foundation Trust), Mairéad G. McNamara(Australian and New Zealand Intensive Care Society), Jennifer J. Knox(National Cancer Center), Juan W. Valle(Cancer Research UK Manchester Institute), Ángela Lamarca(Hospital Universitario Fundación Jiménez Díaz), Sarah P. Blagden(Churchill Hospital), Daniel H. Palmer(University of Liverpool)
Cited by 15
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k